TRAM-39

• UNSPSC Description:

  TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease[1][2][3][4].

• Target Antigen:

  Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/tram-39.html

• Purity:

  99.66

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  N#CC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3Cl

• Molecular Weight:

  303.78

• References & Citations:

  [1]Davies PJ, et al. Different types of potassium channels underlie the long afterhyperpolarization in guinea-pig sympathetic and enteric neurons. Auton Neurosci. 2006 Jan 30;124(1-2):26-30.|[2]Burnham MP, et al. Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br J Pharmacol. 2006 Jun;148(4):434-41.|[3]Ayabe T, et al. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem. 2002 Feb 1;277(5):3793-800.|[4]Wulff H, et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  197525-99-8